is tirzepatide still in shortage The recent announcement that has been removed from the FDA's drug list good news for people looking for effective weight loss solutions. But, it could mean the compounded versions GLP-1 No Longer on FDA's

In the SURMOUNT-1 trial, adults with obesity (but without diabetes) receiving tirzepatide 15 mg weekly achieved an average weight loss of 20.9% over 72 weeks, compared to 3.1% with placebo

3,4 Updates have also been made regarding obesity and weight management for the prevention and treatment of type 2 Diabetes

Switching to alternative GLP-1 receptor agonists might be considered

So if you have cardiovascular disease, your doctor can help determine whether another treatment option is better for you

Our programs include GLP-1S and GLP-1T, compounded versions of GLP-1 medications, all prescribed and monitored by our medical team

Why Fatigue Peaks in the First Month of GLP-1 Treatment Clinical experience shows that GLP-1-related fatigue is most pronounced during the first 3-6 weeks, especially as doses increase